|1.||Schwartz, Brian: 7 articles (08/2015 - 01/2011)|
|2.||Abbadessa, Giovanni: 3 articles (01/2013 - 12/2011)|
|3.||Waghorne, Carol: 3 articles (12/2012 - 04/2011)|
|4.||Chai, Feng: 3 articles (12/2012 - 04/2011)|
|5.||France, Dennis S: 3 articles (01/2012 - 06/2010)|
|6.||Hirashima, T: 2 articles (10/2015 - 06/2013)|
|7.||Akinaga, S: 2 articles (10/2015 - 06/2013)|
|8.||Takahashi, T: 2 articles (10/2015 - 06/2013)|
|9.||Yamamoto, N: 2 articles (10/2015 - 06/2013)|
|10.||Sequist, Lecia V: 2 articles (08/2015 - 09/2012)|
06/01/2013 - "The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors."
12/01/2012 - "This study assessed the activity of tivantinib (ARQ 197), a selective MET inhibitor, in patients with MiT-associated tumors. "
12/15/2011 - "A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors."
06/01/2010 - "Cumulatively, these data suggest that ARQ 197, currently in phase II clinical trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation."
06/01/2010 - "Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2015 - "Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines."
06/10/2011 - "ARQ 197 is a clinically advanced, selective, orally bioavailable, and well tolerated c-Met inhibitor, currently in Phase 3 clinical testing in non-small cell lung cancer patients. "
08/20/2015 - "Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer."
09/01/2012 - "We present the rationale and design for MARQUEE, a phase III, randomized, double-blind, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer (NSCLC). "
01/01/2011 - "New data from a global phase II randomized trial comparing a combination of ARQ 197 plus erlotinib with erlotinib/placebo, in endothelial growth factor receptor inhibitor-naïve patients with locally advanced/metastatic non-small cell lung cancer, demonstrate improvement in progression-free and overall survival with combined therapy. "
|3.||Lung Neoplasms (Lung Cancer)
07/01/2014 - "Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation."
10/01/2015 - "A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)."
01/01/2014 - "Cell viability results show that mesothelioma cell lines were sensitive to ARQ 197, NVP-BEZ235 and GDC-0980 inhibitors. "
01/01/2014 - "Here we determined the combinatorial therapeutic efficacy of a new generation small molecule inhibitor of MET, ARQ 197, and dual PI3K/mTOR inhibitors NVP-BEZ235 and GDC-0980 in mesothelioma cell and mouse xenograft models. "
01/01/2014 - "Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells."
|5.||Hepatocellular Carcinoma (Hepatoma)
06/01/2015 - "Tivantinib (ARQ197) in hepatocellular carcinoma."
01/15/2013 - "The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral, selective, MET inhibitor. "
01/15/2013 - "A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis."
01/01/2013 - "Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. "
06/01/2010 - "ARQ-197 is an oral, selective c-Met inhibitor under development by ArQule Inc, in partnership with Daiichi Sankyo Co Ltd and Asian licensee Kyowa Hakko Kirin Co Ltd, for the potential treatment of solid tumors, including NSCLC, hepatocellular carcinoma and pancreatic cancer, as well as microphthalmia transcription factor-driven tumors. "
|1.||erlotinib (CP 358,774)
|2.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|7.||Microphthalmia-Associated Transcription Factor
|8.||Adenosine Triphosphate (ATP)
|10.||Epidermal Growth Factor Receptor (EGF Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)